8-K: CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

CARGO Therapeutics announced its first quarter 2024 financial results and provided a business update, highlighting progress in its Phase 2 clinical study for firi-cel and advancements in its preclinical pipeline.

Summary

• CARGO Therapeutics reported its financial results for the first quarter ended March 31, 2024, and provided a business update.
• The company's Phase 2 clinical study for firi-cel (CRG-022) is progressing as planned, with 26 activated trial sites and over 20 patients dosed.
• The Independent Data Monitoring Committee (IDMC) recommended continuation of the FIRCE-1 study without modifications.
• Ongoing follow-up from the Stanford Phase 1 study for firi-cel showed a median overall survival of 25.7 months and a favorable safety profile at the dose level selected for the Phase 2 study.
• The company is also making progress with IND-enabling activities for its preclinical asset, CRG-023, which incorporates a tri-specific CAR T with CD2 co-stimulation.
• CARGO had $375.9 million in cash, cash equivalents, and marketable securities as of March 31, 2024, providing an expected cash runway into 2026.
• Research and development expenses for the first quarter of 2024 were $30.5 million, including $1.7 million of non-cash stock-based compensation expense.
• General and administrative expenses for the first quarter of 2024 were $10.3 million, including $2.2 million of non-cash stock-based compensation expense.
• The net loss for the first quarter of 2024 was $35.8 million, or $0.87 per share.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong clinical progress and a solid cash position, but also acknowledges the inherent risks and losses associated with clinical-stage biotech companies.

Positives

• The Phase 2 FIRCE-1 study is progressing as planned with 26 activated sites and over 20 patients dosed.
• The IDMC's recommendation to continue the FIRCE-1 study without modifications indicates positive safety data.
• The Stanford Phase 1 study follow-up data shows promising efficacy and safety results for firi-cel, with a median overall survival of 25.7 months.
• CARGO has a strong cash position of $375.9 million, providing a cash runway into 2026.
• The company is advancing its preclinical pipeline, including CRG-023, a tri-specific CAR T therapy.

Negatives

• The company reported a net loss of $35.8 million for the first quarter of 2024.
• Research and development expenses were $30.5 million for the quarter.
• General and administrative expenses were $10.3 million for the quarter.

Risks

• The company's ability to obtain necessary capital to fund its clinical programs is a risk.
• The early stages of clinical development of the company's product candidates pose risks.
• There are risks associated with obtaining regulatory approval and successfully commercializing product candidates.
• Undesirable side effects or other properties of the company's product candidates are a risk.
• The company relies on third-party suppliers and manufacturers, including CROs, which poses a risk.
• The outcomes of any future collaboration agreements are uncertain.
• The company's ability to adequately maintain intellectual property rights for its product candidates is a risk.

Future Outlook

The company expects to release interim data from the FIRCE-1 Phase 2 clinical trial in the first half of 2025 and is advancing its next-generation cell therapy pipeline.

Management Comments

• Gina Chapman, President and CEO, stated that the company is off to a strong start to 2024 following their successful IPO.
• Gina Chapman also noted that the Phase 2 study for firi-cel is progressing as planned with 26 activated trial sites, more than 20 patients dosed, positive safety review from the IDMC and continued impressive manufacturing success.
• Gina Chapman highlighted that ongoing follow-up from the Stanford Phase 1 study demonstrated favorable efficacy, durability and safety results, reinforcing their conviction in firi-cel.

Industry Context

This announcement is relevant to the broader cell therapy industry, particularly in the development of CAR T-cell therapies for cancer. The progress of CARGO's firi-cel program and its next-generation pipeline is being closely watched by investors and competitors in the space.

Comparison to Industry Standards

• The reported median overall survival of 25.7 months in the Stanford Phase 1 study for firi-cel is competitive with other CAR T-cell therapies targeting relapsed or refractory large B-cell lymphoma, such as Yescarta and Kymriah.
• The 68% overall response rate and 53% complete response rate are also within the range of efficacy seen in other approved CAR T-cell therapies.
• The company's cash runway into 2026 is a positive sign, as many biotech companies face funding challenges in the current market environment.
• The advancement of the CRG-023 program, a tri-specific CAR T therapy, positions CARGO as a potential leader in next-generation cell therapy technologies.

Management Changes

Stakeholder Impact

• Shareholders will be interested in the clinical progress and financial stability of the company.
• Employees will be impacted by the company's growth and development.
• Patients with LBCL may benefit from the potential of firi-cel.
• Suppliers and manufacturers will be impacted by the company's clinical and commercial activities.
• Creditors will be interested in the company's financial health and cash runway.

Next Steps

• The company will continue to enroll patients in the FIRCE-1 Phase 2 clinical study.
• The company will advance its IND-enabling activities for CRG-023.
• The company will present follow-up data from the Stanford Phase 1 study at the 2024 European Hematology Association (EHA) Congress.
• The company expects to release interim data from the FIRCE-1 study in the first half of 2025.

Key Dates

Keywords

CAR T-cell therapy, firicabtagene autoleucel, firi-cel, CRG-022, CRG-023, Phase 2 clinical trial, LBCL, lymphoma, biotechnology, oncology